Apolipoprotein B and Cardiovascular Risk

Relationship Between Apo B and Atherogenic Lipoproteins

The concentration of apoB provides a good estimate of the total number of atherogenic particles in plasma, according to the European Society of Cardiology, with apoB being the major apolipoprotein of the atherogenic lipoprotein families: Very Low-Density Lipoprotein (VLDL), Intermediate-Density Lipoprotein (IDL), and Low-Density Lipoprotein (LDL) 1

ApoB measurement does not require fasting conditions and is not sensitive to moderately high triglyceride levels, as stated by the European Heart Journal 1
ApoB provides a direct measure of the number of atherogenic particles present in circulation, with one ApoB molecule present on each potentially atherogenic lipoprotein particle 2

Despite its advantages, apoB has not been evaluated as a primary treatment target in statin trials, though several post-hoc analyses suggest it may be a better treatment target than LDL-C, according to the European Heart Journal 1

Multiple studies have shown that apoB is superior to LDL cholesterol in predicting cardiovascular disease events, with a stronger association with cardiovascular risk 2

The pattern of elevated triglycerides, low HDL cholesterol, and increased small, dense LDL particles is captured more accurately by apo B than by LDL cholesterol measurement alone, as noted by the European Heart Journal 3

Very high-risk patients should have an apo B target of <80 mg/dL, corresponding to LDL-C <70 mg/dL, according to the European Heart Journal 3
High-risk patients should have an apo B target of <100 mg/dL, corresponding to LDL-C <100 mg/dL, as recommended by the European Heart Journal 3

Apo B measurement has less laboratory error than LDL cholesterol determination, particularly in patients with hypertriglyceridemia, as stated in the European Heart Journal 3

The European Society of Cardiology recommends Apolipoprotein B as an alternative treatment target to LDL-C, with specific targets of <80 mg/dL for very high-risk patients and <100 mg/dL for high-risk patients, to guide intensification of statin therapy more aggressively than LDL-C alone 4
Very high-risk patients, such as those with established CVD, diabetes with complications, or CKD stage 3-5, should have an Apo B target of <80 mg/dL, corresponding to LDL-C <70 mg/dL 4
High-risk patients, such as those with a 10-year ASCVD risk ≥7.5-10%, diabetes without complications, or multiple risk factors, should have an Apo B target of <100 mg/dL, corresponding to LDL-C <100 mg/dL 4

The European Society of Cardiology suggests initiating high-intensity statin therapy for patients with apo B ≥130 mg/dL, which constitutes a risk-enhancing factor equivalent to LDL-C ≥160 mg/dL 4
Apo B should be used to assess response to statin therapy, with a reduction of 25-45% in apo B levels expected, depending on dose and intensity 4

Apo B identifies high-risk patients missed by LDL-C alone, particularly those with metabolic syndrome, diabetes, or obesity, who frequently have discordantly high apo B relative to LDL-C 4
Apo B measurement has several advantages, including no requirement for fasting, accuracy in the presence of hypertriglyceridemia, and direct particle count, providing a true atherogenic burden 4

Among statin-treated patients at LDL-C goal, significant residual dyslipidemia exists, with only 52% of statin users achieving apo B goals, compared to 64% achieving LDL-C goals 4
Apo B appears to be a better index of adequacy of LDL-lowering therapy than LDL-C, with a strong correlation between apo B and LDL-C (r=0.9), but with discordance identifying patients requiring more aggressive therapy 4